Literature DB >> 19705572

Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats.

Tracie A Paine1, William A Carlezon.   

Abstract

BACKGROUND: Attentional deficits that accompany schizophrenia are not effectively treated by available antipsychotic medications. Disruption of NMDA receptor function is often used to model aspects of this disorder in rodents. We used the 5-choice serial reaction time task (5CSRTT) to characterize attentional deficits caused by acute administration or withdrawal from chronic administration of the NMDA receptor antagonist MK-801, and determine if they are ameliorated by haloperidol or clozapine.
METHODS: Acute studies involved tests in the presence of MK-801: rats were administered haloperidol (0.008-0.125 mg/kg, SC) or clozapine (0.16-2.5 mg/kg, SC) in combination with MK-801 (0.25 mg/kg, IP) prior to daily test sessions. Chronic studies involved tests in the absence of MK-801: following daily tests, rats were administered MK-801 (0.5 mg/kg, IP) and tested 24 h later in the absence or presence of haloperidol or clozapine.
RESULTS: Acute MK-801 disrupted performance: it decreased accuracy while increasing omissions, premature responses, and magazine entries. Haloperidol reduced disruptive effects associated with increased activation, whereas it exacerbated other deficits. Clozapine dose-dependently attenuated several of the MK-801-induced performance deficits. Withdrawal from chronic MK-801 progressively increased omissions and response latencies and decreased premature responding, suggesting an amotivational state. Neither haloperidol nor clozapine ameliorated these performance deficits. DISCUSSION: Acute administration and withdrawal from chronic MK-801 administration produced distinct behavioral profiles in the 5CSRTT. Acute MK-801 impaired attention and impulse control whereas chronic MK-801 withdrawal caused signs consistent with amotivation. Haloperidol and clozapine were more effective at attenuating deficits caused by acute MK-801 administration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19705572      PMCID: PMC2775532          DOI: 10.1016/j.neuropharm.2009.01.004

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  42 in total

1.  Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat.

Authors:  B Grayson; N F Idris; J C Neill
Journal:  Behav Brain Res       Date:  2007-06-29       Impact factor: 3.332

2.  Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia.

Authors:  Vicente Martinez; Martin Sarter
Journal:  Neuropsychopharmacology       Date:  2007-12-19       Impact factor: 7.853

3.  Chronic nicotine and dizocilpine effects on nicotinic and NMDA glutamatergic receptor regulation: interactions with clozapine actions and attentional performance in rats.

Authors:  Amir H Rezvani; Yousef Tizabi; Bruk Getachew; Sheketha R Hauser; D Patrick Caldwell; Christopher Hunter; Edward D Levin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-02-12       Impact factor: 5.067

4.  Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase.

Authors:  M Margarita Behrens; Sameh S Ali; Diep N Dao; Jacinta Lucero; Grigoriy Shekhtman; Kevin L Quick; Laura L Dugan
Journal:  Science       Date:  2007-12-07       Impact factor: 47.728

5.  Haloperidol and clozapine have dissociable effects in a model of attentional performance deficits induced by blockade of NMDA receptors in the mPFC.

Authors:  Marta Baviera; Roberto W Invernizzi; Mirjana Carli
Journal:  Psychopharmacology (Berl)       Date:  2007-10-17       Impact factor: 4.530

6.  Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

Authors:  Terry E Goldberg; Robert S Goldman; Katherine E Burdick; Anil K Malhotra; Todd Lencz; Raman C Patel; Margaret G Woerner; Nina R Schooler; John M Kane; Delbert G Robinson
Journal:  Arch Gen Psychiatry       Date:  2007-10

Review 7.  Modelling prefrontal cortex deficits in schizophrenia: implications for treatment.

Authors:  J A Pratt; C Winchester; A Egerton; S M Cochran; B J Morris
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

8.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Authors:  Richard S E Keefe; Robert M Bilder; Sonia M Davis; Philip D Harvey; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; George Capuano; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Clarence E Davis; John K Hsiao; Jeffrey A Lieberman
Journal:  Arch Gen Psychiatry       Date:  2007-06

Review 9.  Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.

Authors:  H A Nasrallah
Journal:  Mol Psychiatry       Date:  2007-09-11       Impact factor: 15.992

10.  Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.

Authors:  Nurith Amitai; Svetlana Semenova; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2007-05-12       Impact factor: 4.415

View more
  25 in total

1.  Comparative effects of different test day challenges on performance in the 5-choice serial reaction time task.

Authors:  Nurith Amitai; Athina Markou
Journal:  Behav Neurosci       Date:  2011-10       Impact factor: 1.912

Review 2.  CNTRICS final animal model task selection: control of attention.

Authors:  C Lustig; R Kozak; M Sarter; J W Young; T W Robbins
Journal:  Neurosci Biobehav Rev       Date:  2012-06-06       Impact factor: 8.989

3.  Schizophrenia-like attentional deficits following blockade of prefrontal cortex GABAA receptors.

Authors:  Tracie A Paine; Lauren E Slipp; William A Carlezon
Journal:  Neuropsychopharmacology       Date:  2011-04-13       Impact factor: 7.853

4.  Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine.

Authors:  David M Thomson; Allan McVie; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2010-09-29       Impact factor: 4.530

5.  Dopamine D1 receptor activation improves PCP-induced performance disruption in the 5C-CPT by reducing inappropriate responding.

Authors:  S A Barnes; J W Young; S T Bate; J C Neill
Journal:  Behav Brain Res       Date:  2015-11-30       Impact factor: 3.332

6.  Rats tested after a washout period from sub-chronic PCP administration exhibited impaired performance in the 5-Choice Continuous Performance Test (5C-CPT) when the attentional load was increased.

Authors:  Sam A Barnes; Jared W Young; Jo C Neill
Journal:  Neuropharmacology       Date:  2011-05-05       Impact factor: 5.250

Review 7.  Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia.

Authors:  Nurith Amitai; Athina Markou
Journal:  Biol Psychiatry       Date:  2010-05-21       Impact factor: 13.382

8.  The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia.

Authors:  Ayan Ghoshal; P Jeffrey Conn
Journal:  Future Neurol       Date:  2015

9.  Prenatal kynurenine treatment in rats causes schizophrenia-like broad monitoring deficits in adulthood.

Authors:  Britta Hahn; Carolyn H Reneski; Ana Pocivavsek; Robert Schwarcz
Journal:  Psychopharmacology (Berl)       Date:  2017-11-11       Impact factor: 4.530

10.  Inhibition of GABA synthesis in the prefrontal cortex increases locomotor activity but does not affect attention in the 5-choice serial reaction time task.

Authors:  Samuel K Asinof; Tracie A Paine
Journal:  Neuropharmacology       Date:  2012-09-26       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.